Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

Zhejiang University

Status and phase: Not yet enrolling; Phase 2

Conditions: COVID-19 Pneumonia

Treatments: Drug: Placebo; Drug: Jaktinib

Study type: Interventional

Funder types: Other

Identifiers

NCT05672888

ZGJAK-IIT-002

Details and patient eligibility

About

This was a randomized, double-blind, placebo-controlled parallel study.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age, male or female;
• History of COVID-19 infection within 1 week;
• Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and meeting any of the following criteria: With fever, respiratory symptoms; Shortness of breath present,RR ≥30 breaths/min.
• Clear consciousness, Capable and voluntary informed consent.

Exclusion criteria

• Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of the same class, or their excipients, Patients with severe gastrointestinal dysfunction affecting drug absorption;
• Any person meeting criteria for critical pneumonia;
• Patients considered unsuitable for this trial by the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

Jaktinib

Experimental group

Description:

Jaktinib 100mg BID

Treatment:

Drug: Jaktinib

Placebo

Placebo Comparator group

Description:

placebo

Treatment:

Drug: Placebo